24 May 2013
Keywords: Genta, Genasense, Melanoma, Phase III
Article | 24 May 2011
USA-based Genta (OTCBB: GNTA) received a blow yesterday, when it announced that overall survival for patients treated with Genasense (oblimersen ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
24 May 2011
23 May 2013
© 2013 thepharmaletter.com